Piramal Pharma Block Deal: Seller likely to offload 6% stake for around ₹1,750 crore

The seller is seeking to raise approximately ₹1,750 crore through the transaction. The deal may be offered at a minor discount to the current market price (CMP).

First Quarter Results

Piramal Pharma posted a consolidated net loss of ₹69.39 crore for the quarter, compared with a loss of ₹81.7 crore in the same period last year.

ALSO READ | Piramal Pharma temporarily suspends Ahmedabad plant operations due to heavy rainfall

Revenue grew 17.4% year-on-year to ₹2,269.9 crore from ₹1,933.7 crore, while EBITDA surged 82.9% to ₹195.2 crore from ₹106.7 crore. EBITDA margin expanded to 8.6% from 5.5% a year earlier.

Chairperson Nandini Piramal said the company started FY27 on a strong note, with all three businesses delivering mid-to-high teens revenue growth along with meaningful EBITDA margin expansion.

She said the CDMO business recorded broad-based growth across India and overseas sites, supported by healthy request-for-proposal activity, order inflows and strong execution. The Complex Hospital Generics business maintained leadership in key therapies, gained traction in ex-US inhalation anesthesia markets and continued the integration of Kenalog.

ALSO READ | Piramal Pharma sees FY27 growth driven by biotech funding, CDMO orders

The Consumer Healthcare business continued to deliver robust growth, driven by its Power Brands, e-commerce, wider distribution, premiumisation and disciplined brand investments.

Within the consumer healthcare business, Power Brands grew 23% year-on-year and accounted for 53% of sales, while e-commerce revenue rose 40% and contributed 28% of sales. The company also launched the “i-choose” master brand for its women’s intimate care portfolio.

Piramal Pharma said premiumisation, disciplined pricing and cost-optimisation initiatives helped offset raw material inflation and supported EBITDA performance.

The company added that it remains focused on delivering sustained revenue growth and further EBITDA expansion through FY27 while staying agile amid a dynamic external environment.

ALSO READ | Piramal Pharma shares recover from lows, surge 3% after Co affirms FY26 guidance

Shares of Piramal Pharma Ltd ended at ₹212.95, up by ₹2.60, or 1.24%, on the BSE.